You have read all your free articles, to continue reading subscribe to read the rest of this content.
NeuroVive Pharmaceutical has announced the completed recruitment of healthy volunteers in the second part of the company’s ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary mitochondrial disease. The first part of the study, in whAlready a subscriber Login You have read…
Swedish Orphan Biovitrum has announced that it has decided to initiate two clinical programs with Kineret (anakinra) in North America, with the aim of evaluating two new potential indications for Kineret where a significant need for alternative treatment options exists: acute gout and Still's diseaAlready a subscriber Login You have read…
SynAct Pharma has announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the company’s Phase 2a study in patients with rheumatoid arthritis (RA) with high disease activity with the aim to recommend which dose(s) of AP1189 to be brAlready a…
Hansa Medical and Axis-Shield report most promising results from pivotal clinical trial with HBP-analysis. The clinical study was carried out at Emergency Departments both in Sweden and the US through 2011-2013. Results show that HBP-analysis predicts patients with forthcoming severe inflammatoryAlready a subscriber Login You have read all your free…
